Download PDF
CC BY-NC-ND 4.0 · Sleep Sci 2021; 14(S 01): 25-30
DOI: 10.5935/1984-0063.20200083
ORIGINAL ARTICLE

Melatonin serum level, sleep functions, and depression level after bilateral anodal transcranial direct current stimulation in patients with Parkinson’s disease: a feasibility study

Hikmat Hadoush
1   Jordan University of Science and Technology, Rehabilitation Sciences -Irbid - Irbid - Jordan.
,
Ansam Alqudah
1   Jordan University of Science and Technology, Rehabilitation Sciences -Irbid - Irbid - Jordan.
,
Saleem A. Banihani
2   Jordan University of Science and Technology, Medical Laboratory Sciences - Irbid - Irbid - Jordan.
,
Muhammed Al-Jarrah
1   Jordan University of Science and Technology, Rehabilitation Sciences -Irbid - Irbid - Jordan.
,
Akram Amro
3   Al-Quds University, Physiotherapy - Jerusalem - Jerusalem - Palestinian Territories.
,
Salameh Aldajah
4   Isra University, Rehabilitation Sciences -Amman - Amman - Jordan.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Objective: Parkinson’s disease (PD) is associated with non-motor complications such as sleep disturbance and depression. Transcranial direct current stimulation (tDCS) showed therapeutic effects on the motor dysfunctions. However, the potential effects of tDCS therapy on melatonin hormone, sleep dysfunctions, and depression in patients with PD still unclear. This feasibility study aimed to identify any potential changes in melatonin serum level, sleep functions and depression after the bilateral anodal tDCS in patients with PD.

Material and Methods: Tensessions of bilateral anodal tDCS stimulation applied over left and right prefrontal and motor areas were given to twenty-five patients with PD. Melatonin serum level, Pittsburgh sleep quality index, and geriatric depression scale examined before and after tDCS stimulation.

Results: After bilateral anodal tDCS, there was a significant reduction in melatonin serum level, improvement in depression, improvements in overall sleep quality, and sleep latency. Correlations test showed significant associations between melatonin serum level reduction and changes in subjective sleep quality, and sleep duration, as well as between improvements in depression and overall sleep quality, sleep latency, and sleep disturbance.

Conclusion: Bilateral anodal tDCS therapy was a feasible and safe tool that showed potential therapeutic effects on melatonin serum level, sleep quality, and depression level in patients with PD. Although the further large scale and randomized-control trial studies are crucially needed, there is still a need for such a feasibility study to be established before such trials can be implemented as is recommended in the new medical research council guidelines.

Keywords:

Parkinson’s Disease - Melatonin - Sleep - Depression - Transcranial Direct Current Stimulation

Funding source:

This work is supported by the deanship of research at Jordan University of Science & Technology (grant No. 256/2019)




Publication History

Received: 27 June 2020

Accepted: 16 November 2020

Article published online:
30 November 2023

© 2023. Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • 1 Fratiglioni L, Qiu C. Prevention of common neurodegenerative disorders in the elderly. Exp Gerontol. 2009 Jan/Feb;44(1-2):46-50.
  • 2 Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G. Depression in Parkinson’s disease. Am J Psychiatry. 1994;151(7):1010-4.
  • 3 Marsh L. Neuropsychiatric aspects of Parkinson’s disease. Psychosomatics. 2000;41(1):15-23.
  • 4 Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry. 1992 Apr;149(4):443-54.
  • 5 Mehta SH, Morgan JC, Sethi KD. Sleep disorders associated with Parkinson’s disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectr. 2008 Mar;13(Suppl 4):6-11.
  • 6 Silva EJ, Wang W, Ronda JM, Wyatt JK, Duffy J F. Circadian and wake-dependent influences on subjective sleepiness, cognitive throughput, and reaction time performance in older and young adults. Sleep. 2010 Apr;33(4):481-90.
  • 7 Videnovic A, Noble C, Reid KJ, Peng J, Turek F W, Marconi A, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014 Apr;71(4):463-9.
  • 8 Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139(Suppl 1):318-24.
  • 9 Umeno A, Biju V, Yoshida Y. In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer’s disease, Parkinson’s disease, and diabetes. Free Radic Res. 2017 Apr;51(4):413-27.
  • 10 Jiang T, Sun Q, Chen S. Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. Prog Neurobiol. 2016;147:1-19.
  • 11 Arushanyan EB, Naumov SS. Protective role of melatonin in etiology and course of Parkinson’s disease: experimental evidence. Eksp Klin Farmakol. 2016;79(9):38-44.
  • 12 Shen Z, Zhou Z, Gao S, Guo Y, Gao K, Wang H, et al. Melatonin Inhibits neural cell apoptosis and promotes locomotor recovery via activation of the Wnt/beta-catenin signaling pathway after spinal cord injury. Neurochem Res. 2017 Aug;42(8):2336-43.
  • 13 Li L, Zhao Z, Ma J, Zheng J, Huang S, Hu S, et al. Elevated plasma melatonin levels are correlated with the non-motor symptoms in Parkinson’s disease: a cross-sectional study. Front Neurosci. 2020;14:505.
  • 14 Boggio PS, Ferrucci R, Rigonatti SP, Covre P, Nitsche M, Pascual-Leone A, et al. Effects of transcranial direct current stimulation on working memory in patients with Parkinson’s disease. J Neurol Sci. 2006 Nov;249(1):31-8.
  • 15 Hadoush H, Al-Sharman A, Khalil H, Banihani SA, Al-Jarrah M. Sleep quality, depression, and quality of life after bilateral anodal transcranial direct current stimulation in patients with Parkinson’s disease. Med Sci Monit Basic Res. 2018;24:198-205.
  • 16 Hadoush H, Banihani SA, Khalil H, Al-Qaisi Y, Al-Sharman A, Al-Jarrah M. Dopamine, BDNF and motor function postbilateral anodal transcranial direct current stimulation in Parkinson’s disease. Neurodegener Dis Manag. 2018 Jun;8(3):171-9.
  • 17 Lin L, Du Y, Yuan S, Shen J, Lin X, Zheng Z. Serum melatonin is an alternative index of Parkinson’s disease severity. Brain Res. 2014;1547:43-8.
  • 18 Bracht T, Federspiel A, Schnell S, Horn H, Höfle O, Wiest R, et al. Cortico-cortical white matter motor pathway microstructure is related to psychomotor retardation in major depressive disorder. PloS One. 2012;7(12):e52238.
  • 19 Wrobel NH, Farrag MF. A preliminary report on the validation of the geriatric depression scale in Arabic. Clin Gerontol. 2006;29(4):33-46.
  • 20 Miranda PC, Lomarev M, Hallett M. Modeling the current distribution during transcranial direct current stimulation. Clin Neurophysiol. 2006 Jul;117(7):1623-9.
  • 21 Hadoush H, Banihani SA, Khalil H, Al-Qaisi Y, Al-Sharman A, Al-Jarrah M. Dopamine, BDNF and motor function postbilateral anodal transcranial direct current stimulation in Parkinson’s disease. Neurodegen Dis Manag. 2018 Jun;8(3):171-9. – ref. é igual a n. 16.
  • 22 Willis GL. Parkinson’s disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci. 2008;19(4-5):245-316.
  • 23 Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005 Sep;6(5):459-66.
  • 24 Medeiros CA, Bruin PFC, Lopes LA, Magalhaes MC, Seabra ML, Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007 Apr;254(4):459-64.
  • 25 Belaid H, Adrien J, Karachi C, Hirsch EC, François C. Effect of melatonin on sleep disorders in a monkey model of Parkinson’s disease. Sleep Med. 2015 Oct;16(10):1245-51.
  • 26 Gilat M, Jackson AC, Marshall NS, Hammond D, Mullins AE, Hall JM, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease: a randomised controlled trial. Mov Disord. 2020;35(2):344-9.
  • 27 Burton S, Daya S, Potgieter B. Melatonin modulates apomorphineinduced rotational behaviour. Experientia. 1991 May;47(5):466-9.
  • 28 Willis GL, Armstrong SM. A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease. Physiol Behav. 1999 Jul;66(5):785-95.
  • 29 Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci. 2012 Mar;23(2):199-226.
  • 30 Rutten S, Vriend C, Van Den Heuvel OA, Smit JH, Berendse H W, Van Der Werf YD. Bright light therapy in Parkinson’s disease: an overview of the background and evidence. Parkinsons Dis. 2012;2012:767105.
  • 31 Romenets SR, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease -- a randomized study. Parkinsonism Relat Disord. 2013 Jul;19(7):670-5.
  • 32 Zisapel N, Laudon M. Dopamine release induced by electrical field stimulation of rat hypothalamus invitro: Inhibition by melatonin. Biochem Biophys Res Commun. 1982 Feb;104(4):1610-6.
  • 33 Reuss S, Olcese J, Vollrath L. Electrical stimulation of the hypothalamic paraventricular nuclei inhibits pineal melatonin synthesis in male rats. Neuroendocrinology. 1985 Sep;41(3):192-6.
  • 34 Catala M, Canete-Nicolas C, Iradi A, Tarazona F, Tormos J, Pascual-Leone A. Melatonin levels in Parkinson’s disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp Gerontol. 1997;32(4-5):553-8.
  • 35 Hone-Blanchet A, Edden RA, Fecteau S. Online effects of transcranial direct current stimulation in real time on human prefrontal and striatal metabolites. Biol Psychiatry. 2016 Sep;80(6):432-8.
  • 36 Villela D, Atherino VF, Lima LS, Moutinho AA, Amaral FG, Peres R, et al. Modulation of pineal melatonin synthesis by glutamate involves paracrine interactions between pinealocytes and astrocytes through NF-B activation. Biomed Res Int. 2013;2013:618432.
  • 37 Claassen DO, McDonell KE, Donahue M, Rawal S, Wylie SA, Neimat JS, et al. Cortical asymmetry in Parkinson’s disease: early susceptibility of the left hemisphere. Brain Behav. 2016 Dec;6(12):e00573.
  • 38 Murphy M, Riedner BA, Huber R, Massimini M, Ferrarelli F, Tononi G. Source modeling sleep slow waves. Proc Natl Acad Sci U S A. 2009 Feb;106(5):1608-13.
  • 39 Murphy M, Huber R, Esser S, A Riedner BA, Massimini M, Ferrarelli F, et al. The cortical topography of local sleep. Curr Top Med Chem. 2011;11(19):2438-46.
  • 41 Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res. 2009 Aug;201(2):239-43.
  • 41 Brunoni AR, Ferrucci R, Fregni F, Boggio PS, Priori A. Transcranial direct current stimulation for the treatment of major depressive disorder: a summary of preclinical, clinical and translational findings. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct;39(1):9-16.
  • 42 Manenti R, Brambilla M, Benussi A, Rosini S, Cobelli C, Ferrari C, et al. Mild cognitive impairment in Parkinson’s disease is improved by transcranial direct current stimulation combined with physical therapy. Mov Disord. 2016 May;31(5):715-24.
  • 43 Bunney BG, Bunney WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol. 2012 Jun;15(5):695-713.
  • 44 Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging. 2006;23(9):693-721.
  • 45 Schmitt K, Holsboer-Trachsler E, Eckert A. BDNF in sleep, insomnia, and sleep deprivation. Ann Med. 2016;48(1-2):42-51.
  • 46 Scheer FA, Morris CJ, Garcia JI, Smales C, Kelly EE, Marks J, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. Sleep. 2012 Oct;35(10):1395-402.
  • 47 Xu X, Liu D, Zhang Z, Sharma M, Zhao Y. Sleep duration and quality in pregnant women: a cross- sectional survey in China. Int J Environ Res Public Health. 2017 Jul;14(7):817.
  • 48 Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Int J Nurs Stud. 2013 May;50(5):587-92.